1110 related articles for article (PubMed ID: 17340590)
1. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
2. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
3. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
4. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
Brake M; Loertzer H; Horsch R; Keller H
J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
7. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
[TBL] [Abstract][Full Text] [Related]
8. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
9. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
10. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
11. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
12. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
13. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers.
Kim YJ; Ha YS; Kim SK; Yoon HY; Lym MS; Kim MJ; Moon SK; Choi YH; Kim WJ
Clin Cancer Res; 2010 Apr; 16(7):2131-7. PubMed ID: 20233890
[TBL] [Abstract][Full Text] [Related]
14. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
[TBL] [Abstract][Full Text] [Related]
15. Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors.
Palou J; Rodríguez-Rubio F; Millán F; Algaba F; Rodríguez-Faba O; Huguet J; Villavicencio H
Urology; 2009 Jun; 73(6):1313-7. PubMed ID: 19362341
[TBL] [Abstract][Full Text] [Related]
16. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours.
Lebret T; Watson RW; Molinié V; Poulain JE; O'Neill A; Fitzpatrick JM; Botto H
Eur Urol; 2007 Jan; 51(1):161-6; discussion 166-7. PubMed ID: 16828965
[TBL] [Abstract][Full Text] [Related]
17. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
19. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression in bladder primary in situ urothelial carcinoma: evaluation in BCG-unresponsive patients and BCG responders.
Pierconti F; Raspollini MR; Martini M; Larocca LM; Bassi PF; Bientinesi R; Baroni G; Minervini A; Petracco G; Pini GM; Patriarca C
Virchows Arch; 2020 Aug; 477(2):269-277. PubMed ID: 32034486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
